Carbamazepine for epilepsy: A controlled prospective evaluation

James Cereghino, Joseph T. Brock, John C. van Meter, J. Klffin Penry, Lawrence D. Smith, Billy G. White

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

The efficacy, bioavailability, and tolerance of carbamazepine in epilepsy were evaluated in a prospective, double-blind study. The study was made in 45 institutionalized patients whose seizures were not controlled completely by combinations of currently available antiepileptic drugs in adequate dosages as determined by serum concentrations. In this population, carbamazepine was equal in efficacy to phenobarbital or diphenylhydantoin in controlling seizure frequency, and side effects were minimal. Serum concentrations of carbamazepine were measured up to 13.7 mcg per milliliter, with 70 percent of the values ranging from 5 to 10 mcg per milliliter. Individual episodes of transient leukopenia occurred during the 21-day test period, but a statistically significant incidence of leukopenia was not observed.

Original languageEnglish (US)
Pages (from-to)401-410
Number of pages10
JournalNeurology
Volume24
Issue number5
StatePublished - 1974
Externally publishedYes

Fingerprint

Carbamazepine
Epilepsy
Leukopenia
Seizures
Phenytoin
Phenobarbital
Serum
Double-Blind Method
Anticonvulsants
Biological Availability
Incidence
Population
Evaluation
Controlled
Efficacy
Drugs
Tolerance

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Cereghino, J., Brock, J. T., van Meter, J. C., Klffin Penry, J., Smith, L. D., & White, B. G. (1974). Carbamazepine for epilepsy: A controlled prospective evaluation. Neurology, 24(5), 401-410.

Carbamazepine for epilepsy : A controlled prospective evaluation. / Cereghino, James; Brock, Joseph T.; van Meter, John C.; Klffin Penry, J.; Smith, Lawrence D.; White, Billy G.

In: Neurology, Vol. 24, No. 5, 1974, p. 401-410.

Research output: Contribution to journalArticle

Cereghino, J, Brock, JT, van Meter, JC, Klffin Penry, J, Smith, LD & White, BG 1974, 'Carbamazepine for epilepsy: A controlled prospective evaluation', Neurology, vol. 24, no. 5, pp. 401-410.
Cereghino J, Brock JT, van Meter JC, Klffin Penry J, Smith LD, White BG. Carbamazepine for epilepsy: A controlled prospective evaluation. Neurology. 1974;24(5):401-410.
Cereghino, James ; Brock, Joseph T. ; van Meter, John C. ; Klffin Penry, J. ; Smith, Lawrence D. ; White, Billy G. / Carbamazepine for epilepsy : A controlled prospective evaluation. In: Neurology. 1974 ; Vol. 24, No. 5. pp. 401-410.
@article{2ace0565d59d43349e7575909c3188b8,
title = "Carbamazepine for epilepsy: A controlled prospective evaluation",
abstract = "The efficacy, bioavailability, and tolerance of carbamazepine in epilepsy were evaluated in a prospective, double-blind study. The study was made in 45 institutionalized patients whose seizures were not controlled completely by combinations of currently available antiepileptic drugs in adequate dosages as determined by serum concentrations. In this population, carbamazepine was equal in efficacy to phenobarbital or diphenylhydantoin in controlling seizure frequency, and side effects were minimal. Serum concentrations of carbamazepine were measured up to 13.7 mcg per milliliter, with 70 percent of the values ranging from 5 to 10 mcg per milliliter. Individual episodes of transient leukopenia occurred during the 21-day test period, but a statistically significant incidence of leukopenia was not observed.",
author = "James Cereghino and Brock, {Joseph T.} and {van Meter}, {John C.} and {Klffin Penry}, J. and Smith, {Lawrence D.} and White, {Billy G.}",
year = "1974",
language = "English (US)",
volume = "24",
pages = "401--410",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Carbamazepine for epilepsy

T2 - A controlled prospective evaluation

AU - Cereghino, James

AU - Brock, Joseph T.

AU - van Meter, John C.

AU - Klffin Penry, J.

AU - Smith, Lawrence D.

AU - White, Billy G.

PY - 1974

Y1 - 1974

N2 - The efficacy, bioavailability, and tolerance of carbamazepine in epilepsy were evaluated in a prospective, double-blind study. The study was made in 45 institutionalized patients whose seizures were not controlled completely by combinations of currently available antiepileptic drugs in adequate dosages as determined by serum concentrations. In this population, carbamazepine was equal in efficacy to phenobarbital or diphenylhydantoin in controlling seizure frequency, and side effects were minimal. Serum concentrations of carbamazepine were measured up to 13.7 mcg per milliliter, with 70 percent of the values ranging from 5 to 10 mcg per milliliter. Individual episodes of transient leukopenia occurred during the 21-day test period, but a statistically significant incidence of leukopenia was not observed.

AB - The efficacy, bioavailability, and tolerance of carbamazepine in epilepsy were evaluated in a prospective, double-blind study. The study was made in 45 institutionalized patients whose seizures were not controlled completely by combinations of currently available antiepileptic drugs in adequate dosages as determined by serum concentrations. In this population, carbamazepine was equal in efficacy to phenobarbital or diphenylhydantoin in controlling seizure frequency, and side effects were minimal. Serum concentrations of carbamazepine were measured up to 13.7 mcg per milliliter, with 70 percent of the values ranging from 5 to 10 mcg per milliliter. Individual episodes of transient leukopenia occurred during the 21-day test period, but a statistically significant incidence of leukopenia was not observed.

UR - http://www.scopus.com/inward/record.url?scp=0016246691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016246691&partnerID=8YFLogxK

M3 - Article

C2 - 4207990

AN - SCOPUS:0016246691

VL - 24

SP - 401

EP - 410

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 5

ER -